Atara Biotherapeutics’ mission is to develop therapies that have the potential to transform the lives of patients with life threatening and debilitating conditions.
We are applying our technology to harness, and augment, targeted healthy T-cell immunity to develop immunotherapies for the treatment of certain cancers, autoimmune diseases, and severe infections.
Atara’s allogeneic, cytotoxic T lymphocyte (CTL) immunotherapy platform is based on the precision of our CTLs in specifically targeting and recognizing antigens expressed by diseased or cancerous cells. This enables the CTLs to eliminate diseased cells without affecting normal, healthy ones. We are developing libraries of off-the-shelf, ready-to-utilize, therapeutic CTL lines that allow us to match an appropriate therapeutic CTL line from our inventory to each patient’s unique immune profile.